Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

No Definitive Link Found Between Physical Activity and Prostate Cancer

March 1, 2018
By Dave Levitan
Article

A meta-analysis was unable to find a conclusive relationship between physical activity and the risk of prostate cancer, though a reduced risk was suggested.

A large meta-analysis was unable to find a conclusive relationship between levels of physical activity and the risk of prostate cancer, though some suggestion of reduced risk was seen for occupational activity and for some specific cancer subtypes. There was also indication that physical activity after diagnosis of prostate cancer might have a protective effect.

“Knowledge about risk factors of prostate cancer is limited, complicating the formulation of appropriate strategies for the prevention of prostate cancer,” wrote study authors led by Daniela Schmid, MSc, of the University of Regensburg in Germany. “The role of potential modifiable risk factors for the development of prostate cancer such as obesity, smoking, poor diet, and physical activity is less well understood.”

The authors conducted a meta-analysis and review of studies of physical activity and prostate cancer, including 48 cohort studies and 24 case-control studies incorporating a total of 151,748 cases of prostate cancer. The mean age of the study participants at baseline was 61 years. Results were published in Annals of Oncology.

The primary analysis relating physical activity to prostate cancer revealed an association that was close to null, with a relative risk (RR) of 0.99 (95% CI, 0.94–1.04) comparing the highest and lowest categories of activity. The same held true when the case-control and the cohort studies were examined separately.

They then stratified by the domain of physical activity, and found a significant inverse association between long-term occupational activity and total prostate cancer incidence, with an RR of 0.83 (95% CI, 0.71–0.98) and a borderline association with short-term occupational physical activity with an RR of 0.85 (95% CI, 0.72–1.00). However, the long-term significant RR did not remain significant after removal of individual studies from the analysis.

When stratifying by both type of physical activity and subtypes of prostate cancer, further associations were seen. There was an inverse association between long-term recreational physical activity and advanced/aggressive prostate cancer, with an RR of 0.75 (95% CI, 0.60–0.95), though this incorporated only 2 studies. There was also an inverse association between long-term occupational physical activity and non-advanced/non-aggressive prostate cancer, with an RR of 0.51 (95% CI, 0.37–0.71), again with 2 studies.

There was no association seen between pre-diagnosis physical activity and mortality due to prostate cancer. However, there was an inverse association between physical activity after diagnosis and prostate cancer mortality among survivors, with an RR of 0.69 (95% CI, 0.55–0.85), based on 4 studies.

“These associations may represent an indication for a potential protective effect of long-term activity on prostate cancer incidence,” the authors wrote. “However, our findings must be interpreted with caution.” The analysis’s sensitivity to removal of individual studies, and the small number of studies that revealed some of the significant results, make interpretation difficult. “Despite a growing body of literature on physical activity and prostate cancer incidence, evidence for a link between overall physical activity and risk of prostate cancer remains elusive.”

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Related Content
Advertisement

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.

FDA Selects Detalimogene for Manufacturing Pilot Program in NMIBC

Roman Fabbricatore
December 3rd 2025
Article

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.


Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.


Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.

JANX007 Displays Encouraging Safety/Efficacy in Metastatic CRPC

Roman Fabbricatore
December 2nd 2025
Article

Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

Russ Conroy
November 23rd 2025
Article

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.


Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.

MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo

Russ Conroy
November 23rd 2025
Article

Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.

Related Content
Advertisement

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.

FDA Selects Detalimogene for Manufacturing Pilot Program in NMIBC

Roman Fabbricatore
December 3rd 2025
Article

A 6-month CR rate of 62% was observed with detalimogene voraplasmid in treating patients with BCG-unresponsive non–muscle invasive bladder cancer.


Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.


Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.

JANX007 Displays Encouraging Safety/Efficacy in Metastatic CRPC

Roman Fabbricatore
December 2nd 2025
Article

Results from the phase 1b ENGAGER-PSMA-01 trial showed deep PSA reductions and a favorable CRS profile among patients with taxane-naive CRPC.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

Russ Conroy
November 23rd 2025
Article

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.


Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.

MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo

Russ Conroy
November 23rd 2025
Article

Treatment with MCS-8 yielded no serious adverse effects among patients at a high risk of developing prostate cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.